RxDoctor Payments Data

Sungnan Park Davis, MD

Adolescent Medicine · Novi, MINPI 1932291432

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novo Nordisk at 34.4% of the total.

$1,052in general payments, 2019–2025

Across 40 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$361
  • Lilly USA, LLC$282
  • AbbVie$137
  • Cranial Technologies, Inc$61
  • Seqirus USA Inc$28
  • Mayne Pharma Commercial LLC$26
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$1,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,052 in reported general payments places this provider in the 75th percentile of 70 adolescent medicine providers in Michigan.

See all adolescent medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$19,010
Medicare patients
50
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$15,905
Fluticasone Propionate12$1,076
Bupropion XlBupropion Hcl24$868
Gabapentin30$753
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen11$716
Armour ThyroidThyroid,pork15$683
Levothyroxine Sodium48$582
Omeprazole28$493
Celecoxib19$472
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide43$421
Metoprolol Succinate27$421
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$406
Albuterol Sulfate HfaAlbuterol Sulfate14$389
Duloxetine Hcl11$353
Amlodipine Besylate29$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$282$15,90511 claims
AbbVieArmour Thyroid$137$68315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 70 adolescent medicine providers in Michigan.

Other adolescent medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →